Willow Biosciences Inc (WLLW) - Total Liabilities
Based on the latest financial reports, Willow Biosciences Inc (WLLW) has total liabilities worth CA$3.00 Million CAD (≈ $2.17 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Willow Biosciences Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Willow Biosciences Inc - Total Liabilities Trend (1998–2024)
This chart illustrates how Willow Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Willow Biosciences Inc total assets.
Willow Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Willow Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bri-Chem Corp.
TO:BRY
|
Canada | CA$20.68 Million |
|
Gibb River Diamonds Ltd
AU:GIB
|
Australia | AU$196.15K |
|
Hybrid Financial Services Limited
NSE:HYBRIDFIN
|
India | Rs108.44 Million |
|
Celtic plc
LSE:CCPC
|
UK | GBX89.90 Million |
|
THOR MNG CUFS/1LS- 00001
F:T5MB
|
Germany | €274.00K |
|
Elecster Oyj A
HE:ELEAV
|
Finland | €17.36 Million |
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
UK | GBX93.06 Million |
|
Nexity Global SA
WAR:NXG
|
Poland | zł1.54 Million |
Liability Composition Analysis (1998–2024)
This chart breaks down Willow Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See WLLW equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Willow Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Willow Biosciences Inc (1998–2024)
The table below shows the annual total liabilities of Willow Biosciences Inc from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$2.99 Million ≈ $2.17 Million |
-7.51% |
| 2023-12-31 | CA$3.24 Million ≈ $2.34 Million |
+82.47% |
| 2022-12-31 | CA$1.77 Million ≈ $1.28 Million |
-66.74% |
| 2021-12-31 | CA$5.33 Million ≈ $3.86 Million |
-76.21% |
| 2020-12-31 | CA$22.42 Million ≈ $16.22 Million |
+88.83% |
| 2019-12-31 | CA$11.87 Million ≈ $8.59 Million |
+8896.06% |
| 2018-12-31 | CA$132.00K ≈ $95.49K |
-84.81% |
| 2017-12-31 | CA$869.19K ≈ $628.76K |
-58.27% |
| 2016-12-31 | CA$2.08 Million ≈ $1.51 Million |
+47.86% |
| 2015-12-31 | CA$1.41 Million ≈ $1.02 Million |
+34.60% |
| 2014-12-31 | CA$1.05 Million ≈ $757.03K |
+10.18% |
| 2013-12-31 | CA$949.86K ≈ $687.12K |
-23.13% |
| 2012-12-31 | CA$1.24 Million ≈ $893.82K |
+140.06% |
| 2011-12-31 | CA$514.71K ≈ $372.33K |
+153.17% |
| 2010-12-31 | CA$203.31K ≈ $147.07K |
-37.11% |
| 2009-12-31 | CA$323.26K ≈ $233.84K |
-64.05% |
| 2008-12-31 | CA$899.22K ≈ $650.48K |
+56.58% |
| 2007-12-31 | CA$574.30K ≈ $415.44K |
-10.81% |
| 2006-12-31 | CA$643.90K ≈ $465.79K |
+10.69% |
| 2005-12-31 | CA$581.73K ≈ $420.82K |
-18.76% |
| 2004-12-31 | CA$716.03K ≈ $517.97K |
-26.99% |
| 2003-12-31 | CA$980.68K ≈ $709.41K |
+27.20% |
| 2002-12-31 | CA$770.95K ≈ $557.70K |
+9.57% |
| 2001-12-31 | CA$703.62K ≈ $508.99K |
+27.73% |
| 2000-12-31 | CA$550.87K ≈ $398.49K |
+113.61% |
| 1999-12-31 | CA$257.88K ≈ $186.55K |
+79.77% |
| 1998-12-31 | CA$143.45K ≈ $103.77K |
-- |
About Willow Biosciences Inc
Willow Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. Willow Biosciences Inc. was founded in 20… Read more